drugset
drugset / Trial / NCT04481607

A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3454 Tablets

NCT04481607 ↗

Phase 1 Unknown 96 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a open-label, multicenter, phase I study to evaluate tolerance and pharmacokinetics of TQB3454 tablets in subjects with advanced solid tumor or hematologic tumor.

Timeline

Start
2020-08-24
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject TQB3454 Small molecule — Oral

Indications

No indication recorded.